Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH cancer study on Nexrutine

This article was originally published in The Tan Sheet

Executive Summary

NIH's National Center for Complementary & Alternative Medicine awards two-year grant to AMC Cancer Research Center to study Next Pharmaceuticals' Nexrutine anti-inflammatory dietary supplement ingredient as a prostate cancer preventive agent, the Denver Colo.-based research institute announces Sept. 16. Nexrutine is a plant extract from bark of Phellodendron trees commonly found in Asia. AMC plans to determine the molecular mechanism underlying the ingredient's efficacy. Previous studies by Dr. Pratap Kumar, the proposal's principal investigator, found Nexrutine inhibits prostate cancer cell growth...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS095960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel